midpage
Projects
Sign in to see your projects.
249 F. Supp. 3d 712
S.D.N.Y.
2017
Read the full case

Background

  • Plaintiffs (Direct Purchasers and End‑Payors) allege two overlapping conspiracies among generic makers to fix prices of propranolol capsules (2013–2014) and tablets (2015), producing abrupt, large price hikes after years of falling or stable prices.
  • Complaints rely on pricing data (IMS/WAC), industry characteristics (commodity-like interchangeability, concentrated sellers, barriers to entry), trade‑association meeting attendance, and parallel price increases as circumstantial evidence of agreement.
  • Government investigations into generic pricing (DOJ subpoenas and criminal guilty pleas by two former Heritage executives for price‑fixing in other generics) are pleaded as corroborating circumstance.
  • Defendants moved to dismiss for failure to state a Sherman Act §1 claim and (Heritage & Upsher‑Smith) for lack of personal jurisdiction; End‑Payors also moved on state‑law standing and pleading grounds.
  • The Court denied dismissal of the §1 claims (finding plaintiffs’ plus‑factor allegations sufficient) but dismissed or narrowed several End‑Payor state‑law claims for lack of standing or failure to plead a deceptive practice; it also reaffirmed its earlier order denying dismissal for lack of personal jurisdiction based on nationwide service under the Clayton Act.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Sherman Act §1 plausibility (capsules & tablets) Price data + market structure + trade‑meeting communications + government probes and guilty pleas are "plus factors" that, with parallel pricing, plausibly allege an agreement Price increases can be explained by legitimate business reasons (supply exits, shortages, market dynamics); oligopoly allegations alone are insufficient Denied dismissals: plaintiffs alleged sufficient plus factors (motive, actions against self‑interest, interfirm communications, governmental investigation linkage) to survive Rule 12(b)(6)
Whether price increases were against defendants’ self‑interest Massive, simultaneous increases in commodity products with no plausible supply/demand cause make unilateral profit‑seeking unlikely Firms could risk unilateral price changes; contemporaneous business explanations (exits, raw materials, shortages) suffice Plaintiffs plausibly alleged that such increases were against self‑interest given magnitude, commodity nature, lack of contemporaneous supply/demand justification
End‑Payors’ state‑law antitrust and consumer claims — standing & scope End‑Payors are efficient enforcers with direct chain (manufacturer→wholesaler→pharmacy→end‑payor); damages traceable; alleged purchases in many states Named plaintiffs lack indirect purchases in some states; class certification should resolve state‑law standing Partial grant: standing suffices for states where End‑Payors allege purchases; claims under a set of states dismissed for lack of Article III/state‑law standing; some consumer claims dismissed for not pleading deceptive acts; certain claims dismissed with prejudice (e.g., Alabama antitrust; several state consumer‑protection laws)
Personal jurisdiction / nationwide service of process Nationwide service under Clayton Act allows U.S.‑wide contacts to satisfy due process for Sherman Act claims Nationwide service may violate Fifth Amendment due process; defendants lack sufficient U.S. contacts Denied dismissal: court applies Fifth Amendment minimum‑contacts and reasonableness test using U.S. contacts and finds defendants did not show undue burden; nationwide service constitutional here and jurisdiction proper

Key Cases Cited

  • Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading standard for concerted action requires facts plausibly suggesting agreement)
  • Starr v. Sony BMG Music Entm’t, 592 F.3d 314 (plus‑factor framework and parallel conduct analysis)
  • Gelboim v. Bank of Am. Corp., 823 F.3d 759 (illustrative list of plus factors for inferring conspiracy)
  • Mayor & City Council of Baltimore v. Citigroup, Inc., 709 F.3d 129 (discussing when market structure allegations are insufficient to plead motive)
  • In re Elevator Antitrust Litig., 502 F.3d 47 (government investigations unrelated to alleged conduct are insufficient absent a linkage)
  • United States v. Socony‑Vacuum Oil Co., 310 U.S. 150 (price‑fixing illegal regardless of the mechanism used to fix prices)
  • Burger King Corp. v. Rudzewicz, 471 U.S. 462 (minimum‑contacts and reasonableness factors for personal jurisdiction)
  • Daimler AG v. Bauman, 571 U.S. 117 (limitations on general jurisdiction; discussion of minimum‑contacts and reasonableness)
  • Waldman v. Palestine Liberation Org., 835 F.3d 317 (Fifth Amendment analysis permitting consideration of defendant’s contacts throughout the U.S.)
Read the full case

Case Details

Case Name: In re Propranolol Antitrust Litigation
Court Name: District Court, S.D. New York
Date Published: Apr 6, 2017
Citations: 249 F. Supp. 3d 712; 2017 WL 1287515; 2017 U.S. Dist. LEXIS 53390; 16-CV-09901 (JSR)
Docket Number: 16-CV-09901 (JSR)
Court Abbreviation: S.D.N.Y.
Log In